, 2021 Background and Aims Non-alcoholic fatty liver disease (NAFLD) is characterized by insulin resistance and dysregulated lipid and glucose metabolism.
Lai, Michelle +12 more
core +1 more source
Curcumin and saroglitazar attenuate diet-induced nonalcoholic steatohepatitis by activating the Nrf2 pathway and suppressing ERK1/2 signaling [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Non-alcoholic fatty liver disease (NAFLD) is a chronic steatohepatitis disorder. If left untreated, it can progress to hepatocellular carcinoma.
Reza Afarin +6 more
doaj +1 more source
Effect of saroglitazar in South Indian patients with diabetic dyslipidemia uncontrolled on a moderate-intensity statin and the association of PPAR α and γ gene polymorphisms with its response [PDF]
, 2023 Background: Diabetic dyslipidemia is associated with atherosclerosis risk factors and cardiovascular disease. Saroglitazar is a dual PPAR α and γ agonist approved initially for diabetic dyslipidemia and later for managing non-alcoholic steatohepatitis ...
Selvarajan, Sandhiya +11 more
core +1 more source
Comparison of the anti-inflammatory and antilipidemic activity of diosmin and saroglitazar in a model of nonalcoholic fatty liver induced by a high-fat diet in Wistar rats [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Non-alcoholic fatty liver disease (NAFLD) is the most common liver-related metabolic disorder in the world, with a global prevalence of 25%.
Reza Afarin +6 more
doaj +1 more source
, 2023 Antidiabetic drugs that have a secondary pharmacological effect on angiogenesis inhibition may help diabetic patients delay or avoid comorbidities caused by angiogenesis including malignancies. In recent studies, saroglitazar has exhibited antiangiogenic
Sabina Khan (15333120) +13 more
core +1 more source
Cardiovascular Diabetology, 2019 Background Saroglitazar, a novel dual peroxisome proliferator activated receptor (PPAR) agonist, in clinical trials, has shown an improvement in lipid and glycemic parameters through the PPAR-α and γ agonist actions, respectively.
Upendra Kaul +6 more
doaj +1 more source
Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL).
, 2022 Forest plot of comparison of saroglitazar 4mg versus control on LDL-cholesterol (mg/dL).
Manik Chhabra (10822587) +5 more
core +1 more source
Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL).
, 2022 Forest plot of comparison of saroglitazar 4mg versus control on total cholesterol (mg/dL).
Manik Chhabra (10822587) +5 more
core +1 more source
From ‘Make in India’ to ‘Made in India’: The saroglitazar story
Indian Heart Journal, 2015 Sivasubramanian Ramakrishnan
exaly +3 more sources
Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Diabetic dyslipidaemia poses a therapeutic challenge. New therapies have emerged in this patient subgroup to enhance outcome and improve compliance.
Arijit Ghosh +4 more
doaj +1 more source